FOLH1 and cancer: A study distributed the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire to 30 patients [12], with ages ranging from 50 to 87, who had undergone 177Lu-PSMA-617 therapy from 2014 to 2016.